¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26
±³À°ÀÏÀÚ : 2023-02-26
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ½ÅÀåÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 160,000¿ø      
ºñ°í BRC (ÀüÀÏ) + ARC (3/26):160,000 ¿ø, BRC (1ÀÏ) + ARC (3/26) 120,000 ¿ø BRC (1ÀÏ): 80,000 ¿ø, ¸¸65¼¼ ÀÌ»ó ȸ¿ø, Çлý:¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:00~09:30 Basic renal pathology and evaluation of primary glomerular disease   ±Ç±â¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:30~10:00 An update on the management of IgA nephropathy   °­¼®ÈÖ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:00~10:30 Immunoglobulin- and complement-mediated glomerular diseases with an MPGN pattern of injury  ¹Ú¼±Èñ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:30~11:00 Overview of the pathogenesis and treatment of ANCA-associated GN (ARC ¿¬°è °­ÀÇ)  È«À¯¾Æ(°¡Å縯ÀÇ´ë) 
È޽Ġ02-26  11:00~11:10 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:10~11:40 How to use SGLT2 inhibitor and GLP-1 receptor agonist in diabetic kidney disease (ARC ¿¬°è °­ÀÇ)  ±æÈ¿¿í(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:40~12:10 Pathophysiology of diabetic kidney disease  ¹®ÁÖ¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 12:10~12:40 Optimal treatment of dyslipidemia in diabetic kidney disease   À¯ÅÂÇö(¿¬¼¼ÀÇ´ë) 
½Ä»ç 02-26  12:40~13:30 Lunch Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 13:30~14:00 Evaluation for resistant hypertension in advanced CKD patients  ÀÌÁ¤È¯(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:00~14:30 Treatment of osteoporosis in CKD  ±èÁ°æ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:30~15:00 Optimal management of anemia: EPO, iron, and new therapeutics  °í°­Áö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:00~15:30 Hypertension management in kidney transplant recipients  Á¤Á¾Ã¶(¼­¿ïÀÇ´ë) 
È޽Ġ02-26  15:30~15:40 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:40~16:10 HDF vs. expanded hemodialysis (ARC ¿¬°è °­ÀÇ)  ÀÌ¿µ±â(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:10~16:40 Flow related complication of arteriovenous fistula (ARC ¿¬°è °­ÀÇ)  ¹ÚÈƼ®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:40~17:10 How should we change the PD prescription when adequacy targets are not met?  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºû°íÀ»Àü³²´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2023-02-26
´ÙÀ½±Û ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (1ÀÏÂ÷) : 2023-02-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
362 ÀüºÏ Á¦6ȸ ÀüºÏ´ëÇб³º´¿ø Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ ½ÉÆ÷Áö¾ö : 2018-09-11 0 371 2018-08-08
361 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦17ȸ ¿¬¼ö°­Á : 2018-09-09 0 501 2018-08-08
360 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇаúÀÇ»çȸ 2018 Ãß°èÇмú´ëȸ : 2018-09-09 1 1,065 2018-08-08
359 ¼­¿ï 2018³âµµ ³úÆÄÁ¤µµ°ü¸®À§¿øȸ Á¤±â±³À° : 2018-09-09 0 679 2018-08-08
358 °æ³² Á¦1ȸ µ¿ºÎ°æ³²Çмú´ëȸ : 2018-09-08 0 859 2018-08-08
357 ¼­¿ï °æÈñ´ëÇб³º´¿ø ¹é¹ÝÁõ°ú »ö¼ÒÁúȯ : 2018-09-08 0 849 2018-08-08
356 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ Asthma School 2018 : 2018-09-08 0 383 2018-08-08
355 ¼­¿ï 2018³â ´ëÇѳëÀÎÀçÈ°ÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2018-09-08 0 412 2018-08-08
354 ºÎ»ê 2018 ´ëÇѾȰúÀÇ»çȸ 5Â÷ ½ÉÆ÷Áö¿ò : 2018-09-08 0 726 2018-08-08
353 ºÎ»ê ´ëÇÑôÃß¿Ü°úÇÐȸ ºÎ¿ï°æ ´ë±¸ÇÕµ¿ ôÃßÁöȸ ¼¼¹Ì³ª : 2018-09-08 0 587 2018-08-08
352 ±¤ÁÖ ´ëÇÑôÃß¿Ü°úÇÐȸ 2018 ±¤ÁÖ±¹Á¦Ã´Ãß½ÉÆ÷Áö¿ò : 2018-09-08 0 342 2018-08-08
351 ÃæºÏ Á¦14Â÷ ´ëÀüÃæû¼Ò¾Æ½Å°æÁöȸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 742 2018-08-08
350 ¼­¿ï 2018³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2018-09-07 0 745 2018-08-08
349 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø À̺ñÀÎÈÄ°ú ±Ý¿äÁý´ãȸ : 2018-09-07 0 459 2018-08-08
348 ºÎ»ê ÁÁÀº°­¾Èº´¿ø Áø·á½Ç¿¡¼­ ÈçÈ÷ º¸´Â Áõ»óÀÇ Á¢±Ù°ú Ä¡·á : 2018-09-06 0 688 2018-08-08
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷